New hormone therapies for hot flashes offer enhanced benefits and minimized risk

September 28, 2020

CLEVELAND, Ohio (September 28, 2020)--Hormone therapy remains the best proven method for managing menopause symptoms such as hot flashes. Research continues, however, in the area to identify novel approaches to estrogen therapy that minimize any associated risks. Dr. Hugh Taylor from Yale School of Medicine will discuss some of the latest developments, including fetal estrogens, during the 2020 Pre-Meeting Symposium of The North American Menopause Society (NAMS).

According to Dr. Taylor, a number of improvements have been introduced in the past decade. These include new selective estrogen receptor modulators (SERMs) and the use of estrogens together with SERMs to replace progestins. Fetal estrogens represent one of the newest promising developments. Their unique properties distinguish them from estradiol, although they have some SERM-like properties.

Dr. Taylor noted that estriol and estetrol have entered clinical use with new data revealing promising characteristics. Specifically, estetrol decreases hot flashes and results in favorable cardiovascular changes while counteracting estradiol stimulation of the breast. Estriol similarly acts as a weak estrogen but can counteract some negative effects of estradiol.

"In addition to the already-established benefits, there is also reason to believe that these fetal estrogens may provide added benefits that have yet to be fully explored, making them even more promising," says Dr. Taylor.

"This presentation promises to offer some great insights into the future of hormone therapy," says Dr. Stephanie Faubion, NAMS medical director. "It's important for healthcare providers to understand that these SERMS and estrogens have different biological characteristics, and some may have benefits over others, increasing opportunities for personalizing care for women."
-end-
Drs. Taylor and Faubion are available for interviews before the presentation during the 2020 NAMS Virtual Annual Meeting, which opens on September 28.

For more information on menopause and healthy aging, visit menopause.org.

Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit http://www.menopause.org.

The North American Menopause Society (NAMS)

Related Hormone Therapy Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

Prolonged use of hormone therapy may minimize muscle loss associated with aging
Skeletal muscle mass and strength are critical in helping prevent falls, fractures, and disability.

Reducing the side-effects of prostate hormone therapy with exercise
A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research.

Hormone therapy associated with improved cognition
Estrogen has a significant role in overall brain health and cognitive function.

Why do estradiol levels vary among women using hormone therapy?
CLEVELAND, Ohio (September 24, 2019)--The benefits of hormone therapy (HT) on atherosclerosis relates to achieved estradiol levels among those women who initiate HT early in postmenopause.

Hormone therapy linked to decrease level of diabetes biomarkers
The Women's Health Initiative (WHI) remains one of the most highly quoted when debating the benefits and risks of hormone therapy.

Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Hormone therapy may be best defense against knee osteoarthritis
There is an ongoing debate regarding the relationship between knee osteoarthritis and hormone therapy (HT), with small-scale studies providing mixed results.

Hormone therapy for 'low T' may not be safe for all men
Boosting testosterone levels with hormone supplements may not be safe or appropriate for all men with low testosterone (low T), according to new research.

Artery hardening and thickness not affected by stopping hormone therapy
Heart disease is still the number one killer of US women, and hormone therapy remains a top treatment for menopause symptoms.

Read More: Hormone Therapy News and Hormone Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.